Alteogen

Alteogen Equity

The The Equity of Alteogen (196170.KQ) as of Oct 27, 2026 is 445.19 B KRW. In the previous year, The Equity was 273.59 B KRW — a change of 62.72% (higher).

Equity

445.19 BKRW

YoY

62.72%

Last updated:

In 2025, Alteogen's equity was 445.19 B KRW, a 62.72% increase from the 273.59 B KRW equity in the previous year.

The Alteogen Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2018
66.63 B KRW
Jan 1, 2019
69.98 B KRW
Jan 1, 2020
131.16 B KRW
Jan 1, 2021
136.73 B KRW
Jan 1, 2022
148.76 B KRW
Jan 1, 2023
148.11 B KRW
Jan 1, 2024
273.59 B KRW
Jan 1, 2025
445.19 B KRW
The Alteogen Equity history
YEAREquityYoY
445.19 BKRW+62.72%
273.59 BKRW+84.72%
148.11 BKRW-0.43%
148.76 BKRW+8.80%
136.73 BKRW+4.25%
131.16 BKRW+87.42%
69.98 BKRW+5.04%
66.63 BKRW+67.21%
39.85 BKRW-11.90%
45.23 BKRW+17.32%
38.55 BKRW+7.61%
35.82 BKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Alteogen Stock analysis

What does Alteogen do? Alteogen, Inc. generates revenue through its biobetter business segment, developing protein pharmaceuticals and cancer therapies, and its bio similar business segment, focusing on bio similar and animal medicines. The company sells growth hormone, herceptin, humira, antibodies, and other products primarily to healthcare providers and pharmaceutical distributors. Its biobetter segment targets oncology and protein-based treatments, while the bio similar segment serves both human and animal health markets with cost-effective alternatives to branded drugs. The firm's product portfolio includes growth hormone, herceptin, and humira, which are key revenue drivers in the biopharmaceutical sector. Herceptin and humira are well-established anticancer drugs, while growth hormone addresses endocrine disorders. The company's bio similar segment offers affordable versions of these therapies, appealing to budget-conscious healthcare systems and veterinary markets. Sales are concentrated in the human and animal medicine sectors, leveraging its dual focus on biobetter and bio similar products. Alteogen is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Alteogen's Equity

Alteogen's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Alteogen's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Alteogen's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Alteogen's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Alteogen’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Alteogen stock

The Equity of Alteogen is 445.19 B KRW in 2025.

The Equity of Alteogen changed from 273.59 B KRW to 445.19 B KRW, representing a 62.72% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Equity Alteogen since 2006 – with annual values, charts, and detailed analysis.

The Equity's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Alteogen historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Alteogen

All Key Metrics — Alteogen